WO2009157006A1 - Process of preparing ebastine - Google Patents
Process of preparing ebastine Download PDFInfo
- Publication number
- WO2009157006A1 WO2009157006A1 PCT/IN2008/000504 IN2008000504W WO2009157006A1 WO 2009157006 A1 WO2009157006 A1 WO 2009157006A1 IN 2008000504 W IN2008000504 W IN 2008000504W WO 2009157006 A1 WO2009157006 A1 WO 2009157006A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ebastine
- solvent
- organic solvent
- reaction
- ethyl acetate
- Prior art date
Links
- 0 CCC(*)(CC1)c(cc2)c1cc2C(CCCCl)=O Chemical compound CCC(*)(CC1)c(cc2)c1cc2C(CCCCl)=O 0.000 description 5
- MJJALKDDGIKVBE-UHFFFAOYSA-O CC(C)(C)c(cc1)ccc1C(CCCN(CC1)CCC1OC(c1ccccc1)c1ccccc1)=[OH+] Chemical compound CC(C)(C)c(cc1)ccc1C(CCCN(CC1)CCC1OC(c1ccccc1)c1ccccc1)=[OH+] MJJALKDDGIKVBE-UHFFFAOYSA-O 0.000 description 1
- QILSFLSDHQAZET-UHFFFAOYSA-N OC(c1ccccc1)c1ccccc1 Chemical compound OC(c1ccccc1)c1ccccc1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N OC1CCNCC1 Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
Definitions
- This invention relates to a novel process for the preparation of ebastine.
- the invention also relates to process of preparation of 1-[4-(1 , 1 -dimethyl ethyl) phenyl]- 4-(4-hydroxy piperidin-1-yl) butan-1-one (compound II), an intermediate or preparation of ebatine
- Ebastine 1-[4-(1 ,1-Dimethylethyl)-phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone, commonly known as Ebastine.
- Ebastine is discovered and developed by Fordonal. The structure of ebastine is given below.
- Ebastine is generally prepared from 1-[4-(1 , 1-dimethyl ethyl) phenyl]-4-(4-hydroxy piperidin-1-yl) butan-1-one and diphenyl methyl bromide.
- Several methods for the preparation ebastine are known in literature.
- the above-disclosed scheme has several disadvantages, which are as follows:
- the compound (II) is purified in the form of fumarate salt and further it reacts with compound (III).
- the compound (III) is highly unstable and moisture sensitive. More over the compound (III) is costlier. Also the process requires refluxing the reaction mixture for more than 36 hours with addition of compound (III) at every 12 hours time interval.
- An object of the present invention is to provide a process of preparing ebastine.
- Another object of the present invention is to provide a process of preparing ebastine wherein the process requires about 6 hours time.
- the present invention is to provide a process of preparing pure ebastine with purity not less than 99.6 %.
- Another object is to provide a process for preparation of compound Il which is an intermediate for formation of ebastine.
- a process for preparation of ebastine comprising reaction of 1-[4-(1 , 1-dimethyl ethyl) phenyl]-4-(4-hydroxy piperidin-1-yl) butan-1-one compound (II) and diphenyl methanol in presence of dehydrating agent in organic solvent system to obtain ebastine fumarate salt (compound IV) in organic solvent.
- the present invention relates to an efficient and cost effective method of synthesis of ebastine comprising the preparation of 1-[4-(1 , 1-dimethyl ethyl) phenyl]-4-(4- hydroxy piperidin-1-yl) butan-1-one by reacting 1 -(4-terf-butylphenyl)-4- chlorobutan-1-one and 4-hydroxy piperidine in organic solvent system in basic condition in one aspect and refluxing the 1-[4-(1 , 1-dimethyl ethyl) phenyl]-4-(4- hydroxy piperidin-1-yl) butan-1-one thus obtained with diphenyl methanol in presence of dehydrating agent by removing the generated water as an azeotrope in another aspect.
- the crude ebastine is purified by making fumarate salt.
- the Ebastine fumarate salt is suspended in organic solvent in presence of base stirred for 30 minutes and organic layer is separated. Distilled out solvent completely under vacuum and crystallize
- the present invention relates to a novel process for preparing ebastine that eliminates the disadvantages of prior art processes for the synthesis of 1- [4-(1 , 1- dimethyl ethyl) phenyl]-4-(4-hydroxy piperidin-1-yl) butan-1-one (II) and also eliminate extensive purification requirements.
- the present invention provides a process of preparing the ebastine, which has following synthetic scheme:
- the coupling reaction between compound (I) and 4-hydroxy piperidine is carried out in presence of a base in organic solvent system, wherein organic solvent is selected from water miscible solvent such as acetonitrile, dioxane. N, N-dimethyl formamide, acetone etc and water immiscible solvent such as toluene, methyl isobutyl ketone, dichlomethane, xylene, chloroform, cyclohexane and mixtures thereof.
- the reaction is carried out in the presence of toluene.
- the base employed can be selected from organic and inorganic bases.
- the organic base can be selected from alkali metal carbonate or bicarbonate such as sodium carbonate, potassium carbonate, sodium bicarbonate or potassium bicarbonate and metal hydroxides such as lithium hydroxide, sodium hydroxide, or potassium hydroxide.
- the organic base can be selected from triethylamine, diisopropyl ethylamine or pyridine.
- the preferred base is sodium bicarbonate.
- the reaction can be carried out from ambient temperature to reflux temperature of the solvent and it generally takes 6-12 hours to go to completion. Typically the reaction is carried out at refluxing temperature of the solvent for about 6-8hours.
- the solvent is distilled out under vacuum and the resulting residue is dissolved in ethyl acetate and water.
- the organic layer pH is adjusted to acidic with mineral acids such as hydrochloric acid, sulphuric acid or acetic acid. The preferred pH is 2-3 and preferred acid is HCI.
- acidic pH the aqueous layer is washed with organic solvent to remove impurities, the desired product is obtained from a mixture of ethyl acetate and n-Hexane directly without any further purification.
- ebastine can be prepared by refluxing compound (II) with diphenyl methyl bromide or chloride in presence of sodium carbonate.
- compound (II) and diphenyl methanol are reacted in presence of dehydrating agent in organic solvent system, wherein organic solvent can be selected from high boiling solvent such as toluene, xylene, methyl isobutyl ketone or dichloroethane.
- organic solvent can be selected from high boiling solvent such as toluene, xylene, methyl isobutyl ketone or dichloroethane.
- the preferred solvent is toluene.
- the dehydrating agent can be selected from p-toluene sulphonic acid monohydrate (PTSA), sulphuric acid, methane sulphonic acid, phosphorous pentoxide, titanium tetrachloride or Dicyclohexylcarbodiimide (DCC) etc.
- the preferred dehydrating agent is p-toluene sulphonic acid monohydrate.
- the reaction can be carried out at refluxing temperature of the solvent to remove water as an azeotrope for about 6-16 hours. Preferably 6-8 hours. After the reaction has proceeded to a desired stage as judged by HPLC analysis.
- the desired compound (IV) is isolated in the form fumarate salt in organic solvent.
- the organic solvent can be selected from alcohols such as methanol, ethanol or isoproppanol; nitriles such as acetonitrile or propionitrile; esters such as ethyl acetate, propyl acetate or butyl acetate; toluene, methyl isobutyl ketone and mixtures thereof.
- the preferred solvent is ethyl acetate.
- a pure ebastine is obtained by breaking ebastine fumarate salt (IV) using base.
- the base is selected from alkali metal hydroxides, carbonates or bicarbonates, ammonia, tertiary amines and mixtures thereof.
- the preferred base is sodium hydroxide.
- a pure ebastine is crystallized from resulting residue obtained from breaking ebastine fumarate salt (IV) in presence of organic solvent at -5 to +25° C.
- the organic solvent is selected from CrC 6 alcohols such as methanol, ethanol, and propanol; hexanes, cyclohexane; diisopropyl ether and mixtures thereof.
- the preferred solvent is methanol.
- the present invention can be illustrated in one of its embodiments by the following non-limiting examples.
- a mixture of 4-hydroxy piperidine (10.2g, 0.1 mol), 1 -(4-terf-butylphenyl)-4- chlorobutan-1-one (24.1g, 0.1 mol) and triethyl amine (20.2g, 0.2mol) in methyl isobutyl ketone (100ml) is refluxed for 6-8hrs.
- the progress of the reaction is monitored by HPLC.
- the reaction mass is cooled to room temperature and washed with water.
- the organic layer pH is adjusted to 2-3 with 3N HCI solution; the aqueous layer is washed with methyl isobutyl ketone and makes the aqueous solution alkaline with aqueous sodium hydroxide and extracted with ethyl acetate.
- the ebastine fumarate salt (24Og) is suspended in ethyl acetate (900ml) and 10% sodium hydroxide solution (800ml), stirred for O. ⁇ hours at room temperature to get a clear solution. Separate the organic layer and wash with water till pH comes to neutral. Distill out solvent completely under vacuum and crystallize the resulting residue from methanol. The obtained pure ebastine solid is filtered and dried at 60 - 65 0 C. Yield: 15Og (64%); Melting point: About 86°C.Purity by HPLC: 99.9%
- the ebastine fumarate salt (20Og) is suspended in ethyl acetate (800ml) and 10% sodium hydroxide solution (700ml), stirred for O. ⁇ hours at room temperature to get a clear solution. Separate the organic layer and washed with water till pH comes too neutral. Distill out solvent completely under vacuum and crystallize the resulting residue is from methanol. The obtained pure ebastine solid is filtered and dried at
- the resulting residue is refluxed with ethyl acetate and fumaric acid (14.3g, 0.12mol).
- the obtained ebastine fumarate salt is filtered, washed with ethyl acetate and dried at 80-85 0 C.
- the ebastine fumarate salt (25g) is suspended in ethyl acetate (150ml) and 10% sodium hydroxide solution (100ml), stirred for O. ⁇ hours at room temperature to get a clear solution. Separate the organic layer and washed with water till pH comes too neutral. Distill out solvent completely under vacuum and crystallize the resulting residue from methanol. The obtained pure Ebastine solid is filtered and dried at 60 - 65 0 C. Yield: 12g (31%); Melting point: About 86 0 C. Purity by HPLC: 99.7%
- the ebastine fumarate salt (14Og) is suspended in ethyl acetate (500ml) and 10% sodium hydroxide solution (350ml), stirred for O. ⁇ hours at room temperature to get a clear solution. Separate the organic layer and washed with water till pH comes too neutral. Distilled out solvent completely under vacuum and crystallize the resulting residue from methanol. The obtained pure ebastine solid is filtered and dried at 60 - 65 0 C. Yield: 75 g (48%); Melting point: About 86 0 C. Purity by HPLC: 99.9%
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1560CH2008 | 2008-06-26 | ||
IN1560/CHE/2008 | 2008-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009157006A1 true WO2009157006A1 (en) | 2009-12-30 |
Family
ID=40151546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000504 WO2009157006A1 (en) | 2008-06-26 | 2008-08-11 | Process of preparing ebastine |
Country Status (2)
Country | Link |
---|---|
PT (1) | PT2009157006W (pt) |
WO (1) | WO2009157006A1 (pt) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371817A1 (en) | 2010-04-01 | 2011-10-05 | Arevipharma GmbH | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
WO2012076919A1 (en) * | 2010-12-11 | 2012-06-14 | Micro Labs Limited | Process of preparing ebastine |
CN104101663A (zh) * | 2014-08-01 | 2014-10-15 | 江苏联环药业股份有限公司 | 用高效液相色谱法测定依巴斯汀有关物质的方法 |
CN114671802A (zh) * | 2022-04-14 | 2022-06-28 | 江苏联环药业股份有限公司 | 一种高纯度依巴斯汀的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550116A (en) | 1983-08-05 | 1985-10-29 | Fordonal, S.A. | Piperidine derivatives |
EP0529365A1 (en) * | 1991-08-08 | 1993-03-03 | Kaken Pharmaceutical Co., Ltd. | Diarylmethoxypiperidine derivatives |
WO2004096763A1 (en) * | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders |
-
2008
- 2008-08-11 WO PCT/IN2008/000504 patent/WO2009157006A1/en active Application Filing
- 2008-08-11 PT PT2008000504A patent/PT2009157006W/pt unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550116A (en) | 1983-08-05 | 1985-10-29 | Fordonal, S.A. | Piperidine derivatives |
EP0529365A1 (en) * | 1991-08-08 | 1993-03-03 | Kaken Pharmaceutical Co., Ltd. | Diarylmethoxypiperidine derivatives |
WO2004096763A1 (en) * | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371817A1 (en) | 2010-04-01 | 2011-10-05 | Arevipharma GmbH | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
WO2011121099A2 (en) | 2010-04-01 | 2011-10-06 | Arevipharma Gmbh | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
WO2011121099A3 (en) * | 2010-04-01 | 2012-03-08 | Arevipharma Gmbh | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
DE112011101112T5 (de) | 2010-04-01 | 2013-01-10 | Arevipharma Gmbh | Verfahren zur Herstellung von 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanon und Säureadditionssalzen davon |
WO2012076919A1 (en) * | 2010-12-11 | 2012-06-14 | Micro Labs Limited | Process of preparing ebastine |
CN104101663A (zh) * | 2014-08-01 | 2014-10-15 | 江苏联环药业股份有限公司 | 用高效液相色谱法测定依巴斯汀有关物质的方法 |
CN104101663B (zh) * | 2014-08-01 | 2015-10-14 | 江苏联环药业股份有限公司 | 用高效液相色谱法测定依巴斯汀有关物质的方法 |
CN114671802A (zh) * | 2022-04-14 | 2022-06-28 | 江苏联环药业股份有限公司 | 一种高纯度依巴斯汀的制备方法 |
CN114671802B (zh) * | 2022-04-14 | 2024-05-17 | 江苏联环药业股份有限公司 | 一种高纯度依巴斯汀的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
PT2009157006W (pt) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2181986B1 (en) | Process for the preparation of a precursor of montelukast | |
US10358423B2 (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamdes | |
US7417149B2 (en) | Process for the preparation of Montelukast | |
WO2009141837A2 (en) | Process for preparing posaconazole and intermediates thereof | |
TWI461407B (zh) | 製備4-〔2-(2-氟苯氧基甲基)苯基〕哌啶化合物之方法 | |
JP2009515922A (ja) | モンテルカストを製造するためのプロセスおよびそのための中間体 | |
WO2009157006A1 (en) | Process of preparing ebastine | |
EP2044021B1 (en) | Process for preparing remifentanil, intermediates thereof, use of said intermediates and processes for their preparation | |
JP5191237B2 (ja) | ビタミンb1の前駆体の製造方法 | |
US6495685B1 (en) | Process for preparing piperazine derivatives | |
JP5585822B2 (ja) | 光学活性ニペコチン酸誘導体の製造方法 | |
WO2011161646A2 (en) | Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof | |
WO2015131299A1 (zh) | 手性-1-叔丁氧羰基-3-羟基哌啶的制备以及手性翻转的方法 | |
US20040077900A1 (en) | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | |
US10640467B2 (en) | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | |
JP3647455B2 (ja) | 3−イソオキサゾールカルボン酸の製造方法 | |
US20110040097A1 (en) | Process for preparing lercanidipine hydrochloride | |
SK20192000A3 (sk) | Soli n-terc-butylhydroxylamínu | |
EP0799203A1 (en) | New process for the preparation of sameridine | |
EP1286965B1 (en) | Piperidine compounds and process for providing such | |
JP2003160560A (ja) | トランス−4−置換ピペリジン−2−カルボン酸塩類の製造方法 | |
CA2372763C (en) | New process | |
JPH06336480A (ja) | ピペリジン中間体の精製法 | |
EP2234975A1 (en) | Process for producing pipecolic-2-acid-2 ',6'-xylidide useful as an intermediate for the preparation of local anesthetics | |
JP2004352715A (ja) | N−メチル−n−フェニルアミノアクロレインの合成 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08808157 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08808157 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: PT Ref legal event code: FG4A Effective date: 20121012 |
|
REG | Reference to national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20140211 |